The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin ...

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations, with ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...